Interferon-alpha therapy following autologous peripheral blood stem cell transplantation for adult T cell leukemia/lymphoma.
In the present report, we describe a case of adult T cell leukemia/lymphoma (ATLL), a 58-year-old woman, successfully treated with interferon (IFN)-alpha following autologous peripheral blood stem cell transplantation (auto-PBSCT). The patient remains in remission with full performance status for more than 12 months. Auto-PBSCT reduced the abdominal lymphoma mass and IFN-alpha eliminated residual tumor cells, possibly through the induction of specific T-cell subsets expressing CD3, CD8 on their surfaces and either IFN-gamma or tumor necrosis factor (TNF)-alpha in cytoplasm. We have treated a total of 4 ATLL patients with auto-PBSCT, including the case presented herein. All other patients treated with auto-PBSCT were not followed by adjuvant chemotherapy or cytokine therapy and relapsed within 3 months after auto-PBSCT. This evidence suggests that the therapeutic success of the present case was attributable to the administration of IFN-alpha immunotherapy following auto-PBSCT.
Fujiwara
Hiroshi
H
First Department of Internal Medicine, Center for Chronic Viral Disease, Faculty of Medicine, Kagoshima University, Kagoshima, Japan.
Arima
Naomichi
N
Akasaki
Yuichi
Y
Ohtsubo
Hideo
H
Ozaki
Atsuo
A
Kukita
Toshimasa
T
Matsushita
Kakushi
K
Arimura
Kosei
K
Suruga
Yukio
Y
Wakamatsu
Shinichi
S
Matsumoto
Tadashi
T
Hidaka
Shiroh
S
Eizuru
Yoshito
Y
Tei
Chuwa
C
D000008:Abdominal Neoplasms / Q000628:therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D015368:Human T-lymphotropic virus 1 / Q000187:drug effects; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D012074:Remission Induction; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
D000998:Antiviral Agents; D007155:Immunologic Factors; D016898:Interferon-alpha; D009607:Nitrosourea Compounds; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; C027260:pirarubicin; C020766:ranimustine